<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032079</url>
  </required_header>
  <id_info>
    <org_study_id>LCH-112020</org_study_id>
    <nct_id>NCT05032079</nct_id>
  </id_info>
  <brief_title>Subzero and Scorpion Trial</brief_title>
  <official_title>Pilot Study for the Cryoablation of Ductal Carcinoma In Situ: Subzero and Scorpion Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larkin Community Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larkin Community Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single-institution pilot study examining the feasibility of performing&#xD;
      ultrasound-guided cryoablation to completely ablate breast ductal carcinoma in situ (DCIS).&#xD;
      The study is designed such that patients meeting selection criteria will undergo cryoablation&#xD;
      followed by surgical resection. The pathology of the surgical specimen will be used to&#xD;
      determine the rate of complete tumor ablation. Standard adjuvant therapies otherwise remained&#xD;
      unchanged.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete tumor ablation</measure>
    <time_frame>2 years</time_frame>
    <description>rate of complete tumor ablation defined as no remaining invasive or in situ carcinoma present upon pathological examination of excised tissue</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ductal Carcinoma in Situ</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryoablation</intervention_name>
    <description>single probe ultrasound guided cryoablation</description>
    <other_name>cryosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 18&#xD;
&#xD;
          2. Pre-registration core biopsy:&#xD;
&#xD;
             Unifocal primary ductal carcinoma in situ (DCIS) or atypical ductal hyperplasia (ADH)&#xD;
             bordering on DCIS or DCIS with microinvasion diagnosed by core needle biopsy. NOTE:&#xD;
             Patients with lobular carcinoma, multifocal and/or multicentric ipsilateral breast&#xD;
             cancer are NOT eligible. Patients with contralateral disease will remain eligible.&#xD;
&#xD;
          3. Tumor size &lt; 1.5 cm in greatest diameter. Specifically, the tumor must measure &lt; 1.5&#xD;
             cm in the axis parallel to the treatment probe and &lt; 1.5 cm in the axis anti-parallel&#xD;
             to the treatment probe. Largest size measured by required pre-treatment scans&#xD;
             (mammogram, ultrasound and MRI) will be used to determine eligibility.&#xD;
&#xD;
          4. An ultrasound visible target for cryoablation:&#xD;
&#xD;
             Ultrasound-visible mass or nonmass finding corresponding to the tumor or An&#xD;
             ultrasound-visible biopsy marker placed within 1cm of the biopsied tumor.&#xD;
&#xD;
          5. No prior or planned neoadjuvant chemotherapy for breast cancer.&#xD;
&#xD;
          6. Adequate breast size for safe cryoablation. This will be determined by the&#xD;
             interventional radiologist using a combination of clinical exam and imaging. Site of&#xD;
             target for cryoablation must be greater than 1 cm from the nipple and greater than 1cm&#xD;
             from the closest skin surface.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multifocal of multicentric carcinoma.&#xD;
&#xD;
          2. Pre-registration core biopsy with diagnosis of frank invasive carcinoma (not&#xD;
             microinvasion) or lobular carcinoma.&#xD;
&#xD;
          3. Prior or planned neoadjuvant chemotherapy for breast cancer.&#xD;
&#xD;
          4. Retroglandular breast implants. (Please note that patients with retropectoral implants&#xD;
             are allowed to enroll if they meet all other inclusion criteria.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Plaza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diagnostic Center for Women</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahkeel Allen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Breast Care Center Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roboam Aguirre, MD, DBA</last_name>
    <phone>3052847608</phone>
    <email>raguirre@larkinhospital.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahkeel Allen, MD</last_name>
    <phone>3052713300</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Breast Care Center Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahkeel Allen, MD</last_name>
      <phone>305-271-3300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center for Women</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Plaza, MD</last_name>
      <email>mplaza@femwell.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Larkin Community Hospital</investigator_affiliation>
    <investigator_full_name>Michael Plaza</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

